Medicaid Monitor
Policy Intelligence
Medicaid Monitor
Policy Intelligence
© 2026 Lanphier Ventures, LLC
Informational use only. Not legal or compliance advice.
← All stories
Federal Policy·July 2, 2026

DEA Proposes Schedule I Classification for Synthetic Kratom Compound 7-OH

The Drug Enforcement Administration announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related synthetic kratom compounds as Schedule I controlled substances, placing them in the same regulatory category as heroin and LSD. The classification applies to synthetic versions of the psychoactive compound found in kratom products. If finalized, the scheduling action would prohibit manufacture, distribution, and possession of these substances, with enforcement implications for entities handling these compounds. The timing of implementation and comment period was not specified in the available content.

Why it matters for managed care

Medicaid MCOs covering behavioral health or substance use disorder treatment may need to update formularies, prior authorization protocols, and member communications if kratom-containing products are used by enrollees for pain or opioid withdrawal management.

Behavioral Health · Pharmacy

Read the full article at thehill.com

Share this briefing

You might also like

← All stories

Get the daily briefing.